21 CFR Part 212 · Current Good Manufacturing Practice for Positron Emission Tomography Drugs

§ 212.61 What must I do to ensure the stability of my PET drug products through expiry?

Subpart G - Laboratory Controls Official text on eCFR Amendment history

(a) Stability testing program. You must establish, follow, and maintain a written testing program to assess the stability characteristics of your PET drug products. The test methods must be reliable, meaningful, and specific. The samples tested for stability must be representative of the lot or batch from which they were obtained and must be stored under suitable conditions.

(b) Storage conditions and expiration dates. The results of such stability testing must be documented and used in determining appropriate storage conditions and expiration dates and times for each PET drug product you produce.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 212.61

Form FDA 483 observations citing this section, fiscal years 2013–2024 (Drugs).

  • Use of stability test results 1
  • Samples representative, stored properly 1
  • Stability testing program 1

Amendment history

Federal Register documents that created or amended this section.